Aclaris Therapeutics/$ACRS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
- Ticker
- $ACRS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 71
- Headquarters
- Wayne, United States
- Website
- www.aclaristx.com
ACRS Metrics
BasicAdvanced
$559M
-
-$0.59
-
-
Price and volume
Market cap
$559M
52-week high
$6.60
52-week low
$2.10
Average daily volume
3.5M
Financial strength
Total debt to equity
0.015
Profitability
Gross margin (TTM)
-816.67%
Net profit margin (TTM)
-1,244.09%
Operating margin (TTM)
-1,412.40%
Revenue per employee (TTM)
$90,000
Management effectiveness
Valuation
Price to revenue (TTM)
76.686
Price to book
4.05
Price to tangible book (TTM)
4.05
Growth
Revenue change (TTM)
-59.34%
Earnings per share change (TTM)
-51.95%
3-year revenue growth (CAGR)
-33.16%
3-year earnings per share growth (CAGR)
-29.34%
10-year earnings per share growth (CAGR)
-11.83%
What the Analysts think about ACRS
Analyst ratings (Buy, Hold, Sell) for Aclaris Therapeutics stock.
Analyst projections of the future price of Aclaris Therapeutics stock.
Bulls say / Bears say
ATI-052 showed a roughly 45-day half-life and sustained target inhibition in its healthy-volunteer Phase 1a trial, supporting the prospect of dosing as rarely as once every three months. That could help it stand out if patient trials confirm meaningful benefit. (Aclaris Therapeutics)
ATI-2138 has shown encouraging Phase 2a signals in atopic dermatitis, and Aclaris plans to test it in lichen planus, where no therapies are FDA-approved. Success could give the company a route into an underserved indication as well as its existing inflammatory-disease markets. (Aclaris Therapeutics, Aclaris Therapeutics)
Aclaris says its cash and marketable securities should fund operations through the end of 2028. This gives it time to pursue several clinical programmes and near-term trial readouts without relying on an immediate fundraising round. (Aclaris Therapeutics)
The main biologics still need to prove they work in patients: ATI-052's positive results came from healthy volunteers, while its patient proof-of-concept trials and the placebo-controlled bosakitug readout were still pending in August. If those studies disappoint, the pipeline's clinical case could weaken sharply. (Aclaris Therapeutics, Aclaris Therapeutics)
The runway has been extended partly through substantial share issuance, which dilutes existing holders. Aclaris sold 18.4 million shares in March and a further 7.3 million after June, while its first-half net loss increased to $41.3 million from $30.5 million a year earlier. (Aclaris Therapeutics)
Aclaris must share the economics of its licensed biologics: the Biosion agreement includes up to $125 million in regulatory milestones, up to $795 million in sales milestones and ongoing royalties. These payments are conditional on success, but they could limit the company's share of any eventual commercial returns. (Aclaris Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
ACRS Financial Performance
Revenues and expenses
ACRS Earnings Performance
Company profitability
Upcoming events
No upcoming events
ACRS News
AllArticlesVideos
Funds containing ACRS
Fund name | Fund size | $ACRS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.